Evidence map›Paper›PMID 42472641›Full record

ArticleBritish journal of haematology2026

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.

Wei Yee Chan, Hannah Al-Yousuf, Ho Pui Jeff Lam, Sarah Leong, Jiexin Zheng, Richard Burt, Andrew J Wilson, Ke Xu, Kate Stringaris, Samah Alimam and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Wei Yee ChanUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-0471-2059
Hannah Al-YousufUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-2942-1867
Ho Pui Jeff LamUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Sarah LeongUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-7794-7732
Jiexin ZhengUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Richard BurtUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-2360-7537
Andrew J WilsonUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Ke XuUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-2453-4475
Kate StringarisUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Samah AlimamUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0009-0005-6894-5080
Kavita RajUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-8258-354X
Rajeev GuptaUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Panagiotis KottaridisUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Anish TailorUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0009-0000-6836-8555
Rebecca BurgoyneUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Marc R MansourUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Asim KhwajaUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Rob SellarUniversity College London Hospitals, NHS Foundation Trust, London, UK.
Elspeth M PayneUniversity College London Hospitals, NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0001-5841-778X
Jenny O'NionsUniversity College London Hospitals, NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty-two per cent of patients treated with intention-to-transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain in long-term remission (median follow-up 43 months).

Indexed as

Antineoplastic Combined Chemotherapy Protocolsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationAgedAniline CompoundsAzacitidineBridged Bicyclo Compounds, HeterocyclicFemaleHumansMiddle AgedPyrazinesRecurrenceSulfonamidesTreatment OutcomeUnited KingdomAniline CompoundsAzacitidineBridged Bicyclo Compounds, HeterocyclicFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibPyrazinesSulfonamidesvenetoclaxAMLFLT3gilteritinibreal‐worldvenetoclax

Identifiers

PMID42472641
PMCPMC13570139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.